Pfizer saw its shares jump 14% over two trading days following its agreement with the Trump administration granting a three-year tariff exemption in exchange for increased U.S. drug manufacturing and implementation of 'most favored nation' pricing for Medicaid. Pfizer committed $70 billion toward domestic capital projects and R&D, alongside introducing a direct-to-consumer platform offering significant drug discounts averaging 50%. This deal positions Pfizer as a leader in balancing innovation, affordability, and domestic production.